Dr. Li is an infectious disease physician-scientist at the Brigham and Women’s Hospital and Harvard Medical School. He leads an active clinical and translational laboratory research program focused on viral detection, reservoirs and resistance, especially within the fields of HIV and COVID-19. Dr. Li is the Director of the Harvard University Virology Specialty Laboratory, the Director of the Harvard University Center for AIDS Research Clinical Core, and a member of the AIDS Clinical Trials Group (ACTG) Executive Committee. He is the protocol virologist for A5401/ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19, the protocol Chair of the ACTG A5308 study of ART treatment for HIV-1 controllers, and the Chair of the A5345 study of biomarkers of HIV rebound. Dr. Li also serves as the Deputy Editor for the Infectious Disease Society of America (IDSA) journal Open Forum Infectious Diseases and on the Editorial Advisory Board for the Journal of Infectious Diseases.
At the completion of this educational session, learners will:
- Contrast viral evolution in SARS-CoV-2 with other viruses.
- Compare SARS-CoV-2 persistence versus reinfection.
- Define novel strains of SARS-CoV-2 and their impact on the epidemic.
This CME activity has approved for AMA PRA Category 1 Credit™
for February 17, 2021 as a live activity. This activity will also be available as an enduring activity from February 18, 2021, through February 16, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Jonathan Z. Li (Presenter) has no relevant financial relationships to disclose.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation